Organization & Developments: Boehringer Ingelhelm

Parents

2014: Boehringer pilots inhalers with sensors to encourage patient adherence
2015: Boehringer trims Connecticut workforce as sales suffer
2016: Boehringer Ingelheim to Fund Commercialization of Propeller’s Digital Platform for Asthma, COPD
2016: Boehringer partners with Qualcomm on connected inhaler
2016: MHN 2016: How Boehringer Ingelheim's digital health strategy has evolved since 2011
2017: Boehringer and Lilly tap Inovalon for analytics and more digital health deals
2017: Can Xencor Continue To Rally? - Xencor, Inc. (NASDAQ:XNCR)
2019: Boehringer, MD Anderson build out 'virtual R&D center' for cancer research
2020: Boehringer Ingelheim, Click Therapeutics ink $500M+ digital therapeutics development, commercialization deal
2021: JPM: Boehringer partners with Google to bring quantum computing to biopharma R&D
2022: Boehringer Ingelheim boosts R&D commitment, promises up to 15 new product launches by 2025
2025: #6. Jardiance family (empagliflozin, monotherapy and in combinations with linagliptin and metformin)2 Boehringer Ingelheim and Eli Lilly 2024 Sales: $13.012 billion ($9.671 billion [€8.357 billion] Boehringer Ingelheim + $3.341 billion Eli Lilly) 2023 Sales: $11.287 billion ($8.542 billion [€7.382 billion] Boehringer Ingelheim + $2.745 billion Eli Lilly) % Change: +15.3%
2025: Quantum Computing: Boehringer Ingelheim Pioneers with Google for Pharma R&D
Boehringer Ingelheim Ireland Limited
Boehringer Ingelheim:Business Areas
Boehringer Ingelheim:Organization